In our study, we aimed to determine the prognostic significance of GLUT-1 expression in breast cancer patients, the relationship between GLUT-1 expression level and clinicopathological prognostic parameters, and the effect of neoadjuvant therapy on GLUT-1 expression. The gene discussed is SLC2A1; the disease is breast carcinoma.